* participation in another clinical study (with use of another investigational medical product) within 3 months prior to study treatment start * unwillingness or inability to comply with study procedures * blood test for sars-cov-2 antibodies igm and igg positive * patients with serious basic diseases that affect survival, including blood diseases, cachexia, active bleeding, severe malnutrition, etc. * clinically active malignant disease * previous thrombotic disorder * history of known pulmonary embolism or known secondary anti-phospholipid syndrome * known or suspected hypersensitivity to any components used to culture the admscs, e.g. bsa and sulfur-containing products (e.g., dmso) * major trauma or surgery within 14 days of study treatment start * mental condition rendering the subject (or the subject's legally acceptable representative\[s\]) unable to understand the nature, scope and possible consequences of the study * alcohol, drug, or medication abuse within one year prior to study treatment start * any condition in the investigator's opinion that is likely to interfere with evaluation of the admsc therapy or satisfactory conduct of the study * irreversible severe end-organ failures, such as heart failure/attack, stroke, liver and renal failure due to other disease conditions * patients or family history with hypercoagulable states, such as protein c/protein s deficiency, factor v leiden, prothrombin gene mutation, dysfibrinogenemia, etc. * history of long-term use of immunosuppressive agents * organ transplant in the past 6 months * pregnant, breastfeeding, or desire to become pregnant or unwilling to practice birth control during participation in the study duration, unless surgically sterilized or postmenopausal during the study * patients with severe pulmonary obstructive pneumonia, severe pulmonary interstitial fibrosis, alveolar proteinosis, allergic alveolitis, and other known viral pneumonia or bacterial pneumonia. this includes patients with pulmonary imaging that reveals interstitial lung damage before contracting covid-19. * qt interval shows greater than 450 ms in males and 470 ms in females in the medical histories or during screen ekg test.

* participation in another clinical study (with use of another investigational medical product) within 3 months prior to study treatment start * unwillingness or inability to comply with study procedures * blood test for sars-cov-2 antibodies igm and igg positive * patients with serious basic diseases that affect survival, including blood diseases, cachexia, active bleeding, severe malnutrition, etc. * clinically active malignant disease * previous thrombotic disorder * history of known pulmonary embolism or known secondary anti-phospholipid syndrome * known or suspected hypersensitivity to any components used to culture the admscs, e.g. bsa and sulfur-containing products (e.g., dmso) * major trauma or surgery within 14 days of study treatment start * mental condition rendering the subject (or the subject's legally acceptable representative\[s\]) unable to understand the nature, scope and possible consequences of the study * alcohol, drug, or medication abuse within one year prior to study treatment start * any condition in the investigator's opinion that is likely to interfere with evaluation of the admsc therapy or satisfactory conduct of the study * irreversible severe end-organ failures, such as heart failure/attack, stroke, liver and renal failure due to other disease conditions * patients or family history with hypercoagulable states, such as protein c/protein s deficiency, factor v leiden, prothrombin gene mutation, dysfibrinogenemia, etc. * history of long-term use of immunosuppressive agents * organ transplant in the past 6 months * pregnant, breastfeeding, or desire to become pregnant or unwilling to practice birth control during participation in the study duration, unless surgically sterilized or postmenopausal during the study * patients with severe pulmonary obstructive pneumonia, severe pulmonary interstitial fibrosis, alveolar proteinosis, allergic alveolitis, and other known viral pneumonia or bacterial pneumonia. this includes patients with pulmonary imaging that reveals interstitial lung damage before contracting covid-19. * qt interval shows greater than 450 ms in males and 470 ms in females in the medical histories or during screen ekg test.

- participation in another clinical study (with use of another investigational medical product) within 3 months prior to study treatment start - unwillingness or inability to comply with study procedures - blood test for sars-cov-2 antibodies igm and igg positive - patients with serious basic diseases that affect survival, including blood diseases, cachexia, active bleeding, severe malnutrition, etc. - clinically active malignant disease - previous thrombotic disorder - history of known pulmonary embolism or known secondary anti-phospholipid syndrome - known or suspected hypersensitivity to any components used to culture the admscs, e.g. bsa and sulfur-containing products (e.g., dmso) - major trauma or surgery within 14 days of study treatment start - mental condition rendering the subject (or the subject's legally acceptable representative[s]) unable to understand the nature, scope and possible consequences of the study - alcohol, drug, or medication abuse within one year prior to study treatment start - any condition in the investigator's opinion that is likely to interfere with evaluation of the admsc therapy or satisfactory conduct of the study - irreversible severe end-organ failures, such as heart failure/attack, stroke, liver and renal failure due to other disease conditions - patients or family history with hypercoagulable states, such as protein c/protein s deficiency, factor v leiden, prothrombin gene mutation, dysfibrinogenemia, etc. - history of long-term use of immunosuppressive agents - organ transplant in the past 6 months - pregnant, breastfeeding, or desire to become pregnant or unwilling to practice birth control during participation in the study duration, unless surgically sterilized or postmenopausal during the study - patients with severe pulmonary obstructive pneumonia, severe pulmonary interstitial fibrosis, alveolar proteinosis, allergic alveolitis, and other known viral pneumonia or bacterial pneumonia. this includes patients with pulmonary imaging that reveals interstitial lung damage before contracting covid-19. - qt interval shows greater than 450 ms in males and 470 ms in females in the medical histories or during screen ekg test.

- participation in another clinical study (with use of another investigational medical product) within 3 months prior to study treatment start - unwillingness or inability to comply with study procedures - blood test for sars-cov-2 antibodies igm and igg positive - patients with serious basic diseases that affect survival, including blood diseases, cachexia, active bleeding, severe malnutrition, etc. - clinically active malignant disease - previous thrombotic disorder - history of known pulmonary embolism or known secondary anti-phospholipid syndrome - known or suspected hypersensitivity to any components used to culture the admscs, e.g. bsa and sulfur-containing products (e.g., dmso) - major trauma or surgery within 14 days of study treatment start - mental condition rendering the subject (or the subject's legally acceptable representative[s]) unable to understand the nature, scope and possible consequences of the study - alcohol, drug, or medication abuse within one year prior to study treatment start - any condition in the investigator's opinion that is likely to interfere with evaluation of the admsc therapy or satisfactory conduct of the study - irreversible severe end-organ failures, such as heart failure/attack, stroke, liver and renal failure due to other disease conditions - patients or family history with hypercoagulable states, such as protein c/protein s deficiency, factor v leiden, prothrombin gene mutation, dysfibrinogenemia, etc. - history of long-term use of immunosuppressive agents - organ transplant in the past 6 months - pregnant, breastfeeding, or desire to become pregnant or unwilling to practice birth control during participation in the study duration, unless surgically sterilized or postmenopausal during the study - patients with severe pulmonary obstructive pneumonia, severe pulmonary interstitial fibrosis, alveolar proteinosis, allergic alveolitis, and other known viral pneumonia or bacterial pneumonia. this includes patients with pulmonary imaging that reveals interstitial lung damage before contracting covid-19. - qt interval shows greater than 450 ms in males and 470 ms in females in the medical histories or during screen ekg test.